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Recombinant hirudin (lepirudin) as anticoagulant in intensive treatment of heparin-induced thrombocytopenia type II
care patients treated with continuous hemodialysis. (now commonly referred to as HIT) [1]. After intrave-
Background. Recombinant hirudin (lepirudin) is a potent nous application of hirudin (hirudin refers to recombi-direct thrombin inhibitor, which has been approved for the
nant hirudin throughout the text) in healthy individuals,treatment of heparin-induced thrombocytopenia type II (HIT).
Because the drug is mainly eliminated by the kidneys, a single an elimination half-life of 60 to 100 minutes, a mean
loading dose of hirudin may induce therapeutic anticoagulation total clearance of 170 to 190 ml/min, and a volume of
for up to one week in patients with renal insufficiency. Thus, distribution of 0.28 liter/kg body wt have been reportedthe use of hirudin in critically ill patients with renal failure could
[2, 3]. Hirudin is mainly eliminated by the kidneys.markedly increase their bleeding risk. In this study, hirudin
Hence, the half-life of hirudin is prolonged in patientswas used in critically ill patients with suspected HIT while on
continuous venovenous hemodialysis (CVVHD). with renal insufficiency and may increase from 1.5 to
Methods. Hirudin anticoagulation was performed in seven 50 hours in anuric patients [4]. Published experience in
critically ill patients with suspected HIT. Four patients were
dialysis patients is limited. Preliminary studies showedinitially anuric. Three patients had residual renal function. In
intermittent hemodialysis with hirudin to be possibleall 64 CVVHD treatments (mean duration 12 hr), a polysulfone
high-flux hemodialyzer (0.75 m2) with a dialysate flow rate of without major side effects [5, 6]. In these early studies,
1.5 liter/hr and an ultrafiltration rate of up to 200 ml/hr was hirudin was given for one single dialysis session only. In
used. Hirudin was given either as continuous intravenous infu-
one patient, hirudin was used for more than 50 consecu-sion or as repetitive intravenous boli. Monitoring of anticoagu-
tive dialysis sessions without adverse effects [7].lation was performed by measurements of the systemic acti-
vated partial thromboplastin time (aPTT). Given the prolonged half-life of hirudin in patients
Results. Hirudin dosage had to be individualized according with impaired renal function, a single loading dose of
to the risk of bleeding or clotting. During CVVHD, a continuous
hirudin may induce therapeutic anticoagulation for upintravenous infusion (0.006 to 0.025 mg/kg body wt/hr, N 5 2)
to one week. Thus, the use of hirudin in critically illor repetitive intravenous boli (0.007 to 0.04 mg/kg, N 5 5)
were given. Two patients required blood transfusions prior to patients with renal failure could markedly increase their
and during hirudin treatment. In five patients without a high bleeding risk. A number of patients with proven or sus-
bleeding risk, the hirudin dose was adjusted to achieve the
pected HIT on intermittent hemodialysis were success-target aPTT (1.5 to 2.0 3 baseline) in order to prevent throm-
fully treated with hirudin at our center. In these patients,botic complications or frequent clotting in the extracorporal
circuit. Hirudin dose requirements depended on residual renal adverse reactions, especially bleeding episodes, have not
function and extracorporal clearance. been observed. Being familiar with hirudin anticoagula-
Conclusions. We conclude from these first clinical data that
tion in intermittent hemodialysis, we applied this antico-anticoagulation with hirudin in critically ill patients on continu-
agulant during continuous venovenous hemodialysisous hemodialysis can be performed without excessive bleeding
risk by combining close clinical and laboratory monitoring. The (CVVHD) in critically ill patients with suspected HIT.
hirudin dose has to be reduced because of renal failure, and
may require adjustment for residual or recovering renal func-
tion and extracorporal elimination. METHODS
Patients
Between January and December 1998, seven intensiveRecombinant hirudin (lepirudin, Refludant) has been
approved in both Europe and the United States for the care patients (4 males and 3 females; mean age 57 years,
range 30 to 70) were suspected to have HIT while addi-
tionally requiring continuous hemodialysis because ofKey words: intensive care, acute renal failure, thrombocytopenia, con-
tinuous renal replacement therapy, anticoagulation, bleeding risk. acute renal failure. Suspicion of HIT was based on the
development of thrombocytopenia during heparin treat- 1999 by the International Society of Nephrology
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Table 1. Patient characteristics
Patient no. Age Sex Main diagnoses HIT DIC
1 38 M Alcoholic hepatitis, viral pneumonia yes no
2 70 F Acute pancreatitis, bacterial pneumonia yes no
3 30 F Generalized vasculitis, cardiogenic shock no yes
4 62 F Dilated cardiomyopathy, bacterial pneumonia yes no
5 70 M COPD, bacterial pneumonia yes no
6 69 M CAD, AMI (repeated), cardiogenic shock yes no
7 59 M CAD, aortic endocarditis, viral pneumonia yes no
Abbreviations are: AMI, acute myocardial infarction; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DIC, disseminated intravascular
coagulation; HIT, heparin-induced thrombocytopenia (type II).





Patient Residual diuresis No. of CVVHD Total
no. ml/day sessions hours mean range
1 0–100 30 394 13 2–38
2 0–100 14 100 7 3–20
3 0 7 138 20 16–24
4 800–3000 3 25 8 5–14
5 2750–2950 2 9 4.5 3–6
6 0–100 4 78 20 7–29
7 2600–3800 4 41 10 6–21
CVVHD is continuous venovenous hemodialysis.
Fig. 1. Time course of platelet counts. Day 0 is the day of platelet
count nadir in all patients.
ment, with other causes of thrombocytopenia being less
likely. HIT was proven in six of the seven patients
by means of an enzyme-linked immunosorbent assay Monitoring of hirudin anticoagulation
(ELISA) detecting antibodies against heparin/platelet Monitoring of anticoagulation was performed by re-
factor IV complexes (HPIA; Diagnostica Stago, distrib- petitive measurements of the systemic activated partial
uted by Roche Diagnostica, Basel, Switzerland). Basic thromboplastin time (aPTT) according to standard meth-
patient characteristics are given in Table 1. All patients ods (analyzer, Behring Coagulation System; reagent,
initially presented with systemic inflammatory response Pathromtin SL; both by Dade Behring, Liederbach, Ger-
syndrome, which could be defined as sepsis caused by many).
documented infection in five patients. All patients suf-
fered from multiple-organ dysfunction syndrome. At the Hemodialysis procedure
initiation of hirudin treatment, four patients were anuric, Continuous venovenous hemodialysis was performed
and three patients had residual diuresis (800 to 3800 ml/ with a polysulfone high-flux hemodialyzer (AV400, 0.75
day; Table 2). m2; Fresenius, Bad Homburg, Germany) using a Fresen-
ius ADM08 dialysis machine (Fresenius) with a bicar-
Hirudin anticoagulation bonate dialysate at a flow rate of 1.5 liter/hr. The blood
On suspicion of HIT, anticoagulation was changed flow was 100 ml/min. The ultrafiltration rate depended
from unfractionated heparin (Heparin-Natrium Braun; on the patient’s need (0 to 200 ml/hr).
Braun, Melsungen, Germany) to recombinant hirudin
(lepirudin, Refludant; Hoechst Marion Roussel, Bad So-
RESULTSden, Germany). Because of the high risk of thrombosis
Course of platelet countsin patients with HIT, hirudin was given intravenously.
Anticoagulation strategy was targeted to protect the pa- All patients had developed severe thrombocytopenia
tient from clot formation without inappropriately in- during heparin treatment. The mean platelet counts fell
creasing the bleeding risk. Hirudin was applied either as from 202 6 26/nl to 39 6 3/nl (Fig. 1). The earliest
continuous intravenous infusion or as repetitive intrave- drop in platelet count was observed on day 3 of heparin
treatment. After changing anticoagulation to recombi-nous boli.
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Table 3. Hirudin dosage and corresponding activated partial thromboplastin time
Hirudin dose
Patient Bolus Continuous infusion Mean daily dose Mean aPTT reached Corresponding
no. Diuresis mg/kg body wt mg/kg body wt/hr mg/kg body wt seconds aPTT ratio
1 Anuria 0.013–0.025 — 0.013 45 1.3
2 Anuria 0.009–0.018 — 0.026 44 1.3
3 Anuria 0.007–0.014 — 0.054 48 1.7
4 Polyuria 0.02–0.04 — 0.08 53 1.6
5 Polyuria 0.013–0.027 — 0.08 45 1.3
6 Anuria — 0.006–0.009 0.15 100 3.3
7 Polyuria — 0.013–0.025 0.5 62 1.5
nant hirudin, platelet counts recovered within five to was switched from intravenous boli to intravenous infu-
seven days (Fig. 1). sion after the recovery of renal function and the termina-
tion of continuous hemodialysis treatment (data not
Continuous hemodialysis shown).
Continuous venovenous hemodialysis had to be initi-
Adverse reactionsated because of acute renal failure. Upon anticoagulation
with hirudin, a total of 64 CVVHD treatments was per- No patient developed allergic reactions on hirudin ap-
formed with an overall duration of 785 hours (Table 2). plication. Overt bleeding was not observed. Despite this,
The mean duration of individual continuous hemodialy- two patients (patient 1 and patient 2) required blood
sis treatment was 12 hours, with a range of 3 to 30 hours. transfusion prior to and during hirudin treatment. The
transfusion requirement did not increase upon changing
Hirudin anticoagulation anticoagulation to hirudin.
Anticoagulation with recombinant hirudin had to be
Patients’ outcomeindividualized according to the risk of bleeding or throm-
bosis. In addition, hirudin dose requirements depended Two patients died. One patient (patient 6) suffered
on residual renal function and extracorporal clearance. from repeated acute myocardial infarction. The other
In five patients, hirudin was applied as repetitive intra- patient (patient 3) showed severe refractory vasculitis.
venous boli. In three anuric patients, the respective dose Both died of prolonged cardiogenic shock. Fatal out-
per single intravenous bolus ranged from 0.007 to 0.025 come in both patients was not related to hirudin antico-
mg/kg body wt, corresponding to a mean daily dose of agulation. The five survivors showed no thromboembolic
0.013 to 0.054 mg/kg body wt (Table 3). The mean aPTT events after starting hirudin. They recovered from multi-
reached by this regimen was 44 to 48 seconds (aPTT ple organ dysfunction syndrome. Two initially anuric
ratio 1.3 to 1.7). In two polyuric patients, the dose of patients (patients 1 and 2) and all three polyuric patients
intravenous boli ranged from 0.013 to 0.04 mg/kg body (patients 4, 5 and 7) eventually recovered renal function.
wt, corresponding to a mean daily dose of 0.08 mg/kg Further hemodialysis treatment was not necessary after
body wt in both patients. The mean aPTT in these pa- discharge from the hospital.
tients was 45 and 53 seconds (aPTT ratio 1.3 and 1.6),
respectively (Table 3).
DISCUSSIONIn two patients, hirudin was applied as continuous
Heparin-induced thrombocytopenia type II is a severeintravenous infusion. In one anuric patient (patient 6),
complication of heparin anticoagulation, which in spiteanticoagulation was aimed to markedly reduce the high
of low platelet counts often leads to potentially life-risk of thrombosis. The respective dose was 0.006 to
threatening thromboembolic complications [1, 8]. Upon0.009 mg/kg body wt/hr, resulting in a mean daily dose
suspicion, immediate stop of heparin treatment andof 0.15 mg/kg body wt. With this regimen, the mean
switch to a suitable alternative anticoagulant are manda-aPTT was 100 seconds (aPTT ratio 3.3). Overt bleeding
tory [1], which in Europe is increasingly performed withwas not observed, and blood transfusion was not re-
recombinant hirudin. In patients with renal failure re-quired. The other patient was polyuric (patient 7). Anti-
quiring continuous dialysis, uncertainty exists regardingcoagulation was performed with an intravenous infusion
the safe use of hirudin. In our study of critically ill pa-of hirudin in a dose of 0.013 to 0.025 mg/kg body wt/hr
tients with acute renal failure who were suspected of(mean daily dose 0.5 mg/kg body wt). In this patient, the
having developed HIT, anticoagulation was performedmean aPTT was 62 seconds (aPTT ratio 1.5; Table 3).
In two patients (patients 2 and 4), hirudin application with recombinant hirudin to prevent white clot forma-
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tion sufficiently. Low doses of hirudin were applied to treatment. To minimize bleeding, a mean daily hirudin
dose of only 0.013 mg/kg body wt was given in bolusavoid bleeding complications.
form, which resulted in a mean aPTT of 45 seconds
Laboratory monitoring of hirudin treatment (aPTT ratio 1.3; Table 3). The transfusion requirement
did not increase after switch of anticoagulation to hiru-In HIT patients, hirudin is given to avoid clot forma-
tion, but at the same time the risk of bleeding has to be din. In case of hirudin overdosage, the rapid elimination
of the drug may be required, which could be performedminimized. The ideal laboratory monitoring parameter
should reliably guide anticoagulation between the risk by high-volume hemofiltration using high-flux hemodia-
lyzers [13]. Compared with hemofiltration, hemodialysisof bleeding and clotting. aPTT has frequently been used
to monitor hirudin treatment [9]. However, its adequacy provides lower hirudin elimination, as the high molecular
weight of hirudin impairs diffusion. Thus, if patients arefor monitoring hirudin anticoagulation has been debated
because a correlation with hirudin levels is not linear at treated with hemofiltration, a higher dosage of hirudin
may be required than that used in our study.higher hirudin concentrations [10, 11]. Up to a hirudin
plasma concentration of 0.5 mg/ml, aPTT was found to
Use of hirudin in patients with a high clotting riskbe prolonged linearly in a dose-dependent manner [11].
Above that concentration, a nonlinear relationship be- In our study, one patient suffering from severe coro-
nary artery disease repeatedly developed thromboem-tween hirudin plasma levels and respective aPTT prolon-
gation was observed, resulting in a smaller extent of bolic complications during the prehirudin period (patient
6). Hirudin anticoagulation was thus aimed to reach aaPTT prolongation at higher hirudin concentrations [10,
11]. aPTT appears to be a useful monitoring parameter, high aPTT ratio despite anuria. To avoid clotting, a mean
daily dose of 0.15 mg/kg body wt was applied as continu-provided that hirudin anticoagulation is performed in
the low-dose range, as was done in this study. Clotting ous intravenous infusion, which resulted in a mean aPTT
of 100 seconds (aPTT ratio 3.3). Overt bleeding was nottests based on thrombin time such as activated clotting
time (ACT) are not helpful with regard to hirudin moni- observed, and blood transfusion was not required. When
applying larger doses of hirudin in patients with renaltoring because of their narrow linear dose–response
curve [11]. A recently developed test, ecarin clotting time failure, the use of additional monitoring tests such as
ECT or chromogenic assays for determination of hirudin(ECT) allows the anticoagulation effect to be monitored
with an almost linear correlation to hirudin concentra- plasma levels is recommended, because aPTT may no
longer correlate with hirudin levels and bleeding risk.tions over the whole range from subtherapeutic to toxic
hirudin levels (0.05 to 5.0 mg/ml) [11]. The ECT assay is
Increasing hirudin dose requirements with recovery ofcurrently not commercially available, hindering its broad
renal functionuse as a bedside test. Chromogenic assays for accurate
determination of hirudin plasma levels are commercially Hirudin dosing depends on the volume of extracellular
fluid and on drug elimination by residual renal functionavailable in Europe but are not yet introduced in labora-
tory routine. Since completion of this study, a chromo- and extracorporal elimination, and hirudin removal by
nonrenal clearance pathways can be neglected. Its distri-genic assay for determination of hirudin concentrations
(analyzer, Behring Coagulation System; reagent, Beri- bution volume may increase because of volume substitu-
tion often necessary in critically ill patients. Initially andchrom Hirudin; both by Dade Behring) has been estab-
lished at our center. However, in a large prospective, for maintenance dosing, the same boli were used, guided
by the aPTT response. Increasing renal clearance causedrecently published multicenter study on hirudin treat-
ment of HIT patients, hirudin plasma levels did not cor- by recovering renal function will contribute to necessary
hirudin dose adjustments. When patient 2 was initiallyrelate with bleeding complications [9]. This may be due
in part to sustained antithrombotic activity of hirudin anuric, the mean daily hirudin dose to achieve an aPTT
of 44 seconds (aPTT ratio 1.3) was 0.026 mg/kg bodyeven after its plasma clearance, which is most likely based
on its action on clot-bound thrombin [12]. Because even wt. Upon recovering renal function, dose requirements
increased in correlation to increasing daily urine volume.an accurate test for measurement of hirudin plasma lev-
els may not predict the bleeding risk, we attempted to A mean daily hirudin dose of 1 mg/kg body wt did not
prolong aPTT during that period.keep aPTT levels between 1.5 and 2.0 3 baseline values.
Moreover, repetitive evaluation of the clinical situation In summary, these first clinical data show that antico-
agulation with hirudin in critically ill patients on continu-is mandatory.
ous hemodialysis can be performed without excessive
Use of hirudin in patients with a high bleeding risk bleeding risk by combining close clinical and laboratory
monitoring. The hirudin dose has to be reduced becauseIn our study, one patient suffering from alcoholic hep-
atitis, severe malnutrition, and viral pneumonia (patient of renal failure but requires adjustment for residual or
recovering renal function and extracorporal elimination.1) needed repetitive blood transfusions prior to hirudin
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